Journal
HAEMATOLOGICA
Volume 93, Issue 5, Pages 770-774Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.12265
Keywords
chronic myeloid leukemia; imatinib; long-term results; interferon-alpha
Categories
Funding
- Fondazione del Monte di Bologna e Ravenna
- European LeukemiaNet funds
- BolognAIL
Ask authors/readers for more resources
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-alpha in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-alpha.The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response.These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available